59-Year-Old Man Presents With Low Back Pain & Bone Lesion

Poll

A 59-year-old man presents with lower back pain. Diagnostic imaging reveals the presence of a lesion in the bone in the lower back area. A prostate and bone biopsy are performed. What is your diagnosis?

A 59-year-old man presents with lower back pain.  Diagnostic imaging reveals the presence of a lesion in the bone in the lower back area.  A prostate and bone biopsy are performed and results are shown below, respectively.


 

What is your diagnosis?

A. Benign prostatic hyperplasia and metastatic adenocarcinoma of lung to bone
B. Prostatic adenocarcinoma metastatic to bone
C. Prostatic adenocarcinoma and metastatic adenocarcinoma to bone of unknown origin
D. Prostatic adenocarcinoma and bone negative for tumor

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
2 experts in this video
2 experts in this video
Related Content
The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.

Ziftomenib Earns FDA Priority Review for R/R NPM1-Mutrant AML

Roman Fabbricatore
June 3rd 2025
Article

The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLC

Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLC

Jordyn Sava
June 3rd 2025
Article

Benmelstobart-based regimens provide clinically meaningful PFS benefits as consolidation therapy for unresectable stage III non–small cell lung cancer.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Efficacy and biomarker analyses from CheckMate-77T support perioperative nivolumab as an effective option in resectable NSCLC.

Nivolumab Extends EFS Across Resectable NSCLC Subgroups

Caroline Seymour
June 3rd 2025
Article

Efficacy and biomarker analyses from CheckMate-77T support perioperative nivolumab as an effective option in resectable NSCLC.

An efficacy advantage with osimertinib-containing regimens was consistent across predefined patient subgroups in those with EGFR-mutant NSCLC.

Neoadjuvant Osimertinib Enhances Responses in Resectable EGFR-Mutated NSCLC

Kyle Doherty
June 3rd 2025
Article

An efficacy advantage with osimertinib-containing regimens was consistent across predefined patient subgroups in those with EGFR-mutant NSCLC.